Deutsche Bank Aktiengesellschaft Downgrades Merck KGaA (OTCMKTS:MKKGY) to Hold

Merck KGaA (OTCMKTS:MKKGY) was downgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports.

Merck KGaA Stock Performance

Shares of MKKGY opened at $29.38 on Tuesday. The firm has a market capitalization of $18.99 billion, a P/E ratio of 11.71, a P/E/G ratio of 5.86 and a beta of 0.96. Merck KGaA has a 52 week low of $24.32 and a 52 week high of $31.00. The stock has a 50 day moving average price of $28.90 and a two-hundred day moving average price of $27.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.97 and a current ratio of 1.49.

Merck KGaA (OTCMKTS:MKKGY) last announced its earnings results on Thursday, November 13th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.27. Merck KGaA had a return on equity of 10.07% and a net margin of 13.92%.The company had revenue of $6.17 billion for the quarter, compared to analysts’ expectations of $6.08 billion. Equities analysts forecast that Merck KGaA will post 1.87 earnings per share for the current fiscal year.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.